Bioprecursor prodrugs: Molecular modification of the active principle

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 14, 2010, Pages 1316-1330

  Kokil, Ganesh R ^a   Rewatkar, Prarthana V ^b  

^a Sinhgad Institute of Pharmaceutical Sciences   (India)

^b Kamla Nehru College of Pharmacy   (India)

Author keywords

Active metabolites; Bioprecursor prodrugs; Bioreductive alkylation; Glucuronic acid conjugation; Oxidative activation

Indexed keywords

ANTIDIABETIC AGENT; ARYLACETIC ACID DERIVATIVE; BIOPRECURSOR PRODRUG; BUCLOXIC ACID; CYTOCHROME P450 REDUCTASE; DEXPATHENOL; DRUG METABOLITE; FENBUFEN; FUROBUFENE; GLUTATHIONE; HALOPERIDOL; IDOXURIDINE; INDOMETACIN; METHYLTRANSFERASE; MITOMYCIN; NABUMETONE; NICOTINE; NICOTINIC ACID; NICOTINYL ALCOHOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOTHENIC ACID; PARACETAMOL; PHENACETIN; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SAH 51641; SULFOTRANSFERASE; SULINDAC; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CHEMICAL MODIFICATION; DRUG ACTIVATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DEVELOPMENT; DRUG INHIBITION; DRUG METABOLISM; DRUG OXIDATION; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSFORMATION; FIRST PASS EFFECT; HEMOLYTIC ANEMIA; HUMAN; METHEMOGLOBINEMIA; METHYLATION; PHOSPHORYLATION; PRECURSOR; STOMACH IRRITATION;

ACETYLATION; ANIMALS; HUMANS; METHYLATION; OXIDATION-REDUCTION; PHOSPHORYLATION; PRODRUGS; SULFUR COMPOUNDS;

EID: 78649887240     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955710793564179     Document Type: Article

References (89)

1. Testa, B.; Caldwell, J. Prodrugs revisited: the ad hoc approach as a complement to ligand design. Med. Res. Rev., 1996, 16, 233-241.
2. Sherwood, R.F.; Melton, R.G.; Alwan, S.M. Purification and properties of carboxypeptidase GZ from Pseudomonas sp. strain RS-16: Use of a novel triadne dye affinity method. Eur. J. Biochem., 1985, 148, 447-453.
3. Rao, H. S. Capping drugs: Development of prodrugs. Resonance, 2003, 8(2), 19-27.
4. Albert, A. Chemical aspects of selective toxicity. Nature, 1958, 182, 421-423.
5. Rasheed, A.; Kumar1, C. K. A. Novel approaches on prodrug based drug design. Pharm. Chem. J., 2008, 42 (12), 677-686.
6. Verma, A.; Verma, B.; Prajapati, S.; Tripathi, K. Prodrug as a chemical delivery system: A Review Asian J. Res. Chem., 2009, 2(2), 100-103.
7. Jarvinen, T.; Jarvinen, K. Prodrugs for improved ocular drug delivery.Adv. Drug Deliv. Rev., 1996, 19(2), 203-224.
8. Friend D.R.; Chang G.W. A colon-specific drug-delivery system based on drug glycosides and the glycosidases of colonic bacteria. J. Med. chem., 1984, 27, 261-266.
9. Kawakami S.; Yamishita, F.; Hashida, M. Disposition characteristics of emulsions and incorporated drugs after systemic or local injection. Adv. Drug Deliv. Rev., 2000, 45(1), 77-88.
10. Fernandez, C.; Nieto, O.; Fontenla, J.; Rivas, E. Synthesis of glycosyl derivatives as dopamine prodrugs: interaction with glucose carrier GLUT-1. Org. Biomol. Chem., 2003, 1, 767-771.
11. Lokhandwala, M. F.; Richard, B. J. Dopamine receptor agonists in cardiovascular therapy. Drug Dev. Res., 1983, 3(4), 299-310.
12. Sinkula, A. A.; Yalkowsky, S. H. Rationale for design of biologically reversible drug derivatives: prodrugs. J. Pharm. Sci., 1975, 64, 181-210.
13. Cullen, E. Novel anti-inflammatory agents. J. Pharm. Sci., 1984, 73, 579-589.
14. Guengerich, F. P. Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. Toxicol. Lett., 1994, 70, 133-138.
15. Yamazaki, H.; Nakano, M.; Gillam, E. M.; Bell, L. C. Requirements for cytochrome b5 in the oxidation of 7- ethoxycoumarin, chlorozoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and human liver microsomes. Biochem. Pharmacol., 1996, 52, 301-309.
16. Guengerich, F. P. Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer. Res., 1988, 48, 2946-2954.
17. Cashman, J. R. Some distinctions between flavin-containing and cytochrome P450 monooxygenases. Biochem. Biophys. Res. Commun., 2005, 338, 599-604.
18. Singer, T. Monoamine oxidases old friends hold many surprises. FASEB J., 1995, 9, 605-610.
19. Richards, J. G. Monoamine oxidases: from brain maps to physiology and transgenics to pathophysiology. J. Neural. Transm. Suppl., 1998, 52, 173-187.
20. Johnston, J. P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol., 1968, 17, 1285-1297.
21. Knoll, J. Some puzzling effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol., 1972, 5, 393-408.
22. Youdim, M. Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition. J. Neural. Transm., 1993, 91, 181-195.
23. Saura, J. Differential age-related changes of MAO-A and MAO-B in mouse brain and peripheral organs. Neurobiol. Aging., 1994, 15, 399-408.
24. Pulvin, S.; Legoy, M. D.; Lortie, R. Enzyme technology and gas phase catalysis: Alcohol dehydrogenase example. Biotechnol. Lett., 1986, 8(11), 783-784.
25. Strobel, H. W.; Hodgson, A. V.; Shen, S. In: Cytochrome P450: Structure, Mechanism and Biochemistry, ed. Ortiz de Montellano, P. R. Ed. Plenum, New York, 2005, pp. 225-244.
26. Pederson, T. C.; Austin, R. H.; Gunsalus, I. C. In: Microsomes and Drug Oxidations, Ullrich, V.; Ed. Pergamon Press Ltd., Oxford, 1977, pp. 275-283.
27. Hintz, M. J.; Peterson, J. A. The kinetics of reduction of cytochrome P-450cam by reduced putidaredoxin. J. Biol. Chem., 1981, 256, 6721-6728.
28. Brewer, C. B.; Peterson, J. A. Single turnover kinetics of the reaction between oxycytochrome P450cam and reduced putidaredoxin., J. Biol. Chem., 1988, 263, 791-798.
29. Friedel, H. A.; Langtry, H. D. Nabumetone: a reappraisal of its pharmacology and therapeutic use in rheumatoid diseases and pain states. Drugs, 1993, 45, 131-156.
30. Hanck, A. B.; Goffin, H. Dexpanthenol (Ro 01-4709) in the treatment of constipation. Acta. Vitaminol. Enzymol., 1982, 4, 87-97.
31. DiPalma, J. R.; Thayer, W. S. Use of Niacin as a Drug, Annu. Rev. Nutr., 1991, 11, 169-187.
32. Duggan, D. E.; Hooke, K. F.; Hwang, S. S. Kinetics of the tissue distributions of sulindac and metabolites. Relevance to sites and rates of bioactivation. Drug. Metab. Dispos., 1980, 8(4), 241-6.
33. Shen, T. Y.; Winter, C. A. Chemical and biological studies on indomethacin, sulindac and their analogs. Adv. Drug Res., 1977, 12, 90-245.
34. Cox, P. J.; Farmer, P. B.; Foster, A. B.; Gilby, E. D.The use of deuterated analogs in qualitative and quantitative investigations of the metabolism of cyclophosphamide (NSC-26271). Cancer Treat. Rep., 1976, 6, 483-491.
35. Mcdonnell, W. M.; Scheiman, J. M. Induction of cytochrome P450 IA genes (CYP 1A) by omeprazole in the human alimentary tract. Gastroenterology, 1992, 103, 1509-1516.
36. Aicher, T. D.; Bebernitz, G. R.; Bell, P. A.; Brand, L. J.; Dain, J. G.; Deems, R.; Fillers, W. S. Hypoglycemic prodrugs of 4-(2,2- dimethyl-1-oxopropyl)benzoic acid. J. Med. Chem., 1999, 42 (1), 153-163.
37. Lee, M. J.; Breese, C. R.; Strook, M. L. The effect of nicotine and haloperidol co-treatment on nicotinic receptor levels in the rat brain. Mol. Brain. Res., 2001, 86(1-2), 115-124.
38. Gillard, J. W.; Belanger, P. Metabolic synthesis of arylacetic acid antiinflammatory drugs from arylhexenoic acids. 2. Indomethacin. J. Med. Chem., 1987, 30 (11), 2051-2058.
39. Shen, T. Y. Perspectives in non-steroidal anti-inflammatory agents. Angew. Chem. Int. Ed. Engl., 1972, 11, 460-472.
40. Oberg, B.; Johansson, N.-G. The relative merits and drawbacks of new nucleoside analogues with clinical potential. J. Antimicrob. Chemother., 1984, 14, 5-26.
41. Krenitsky, T. A.; Hall, W. W.; de Miranda, P.; Beauchamp, L. M. 6-Deoxyacyclovir: a xanthine oxidaseactivated prodrug of acyclovir. Proc. Natl. Acad. Sci. USA, 1984, 81, 3209-3213.
42. Chung, T. K.; Funk, M. A. L-2-Oxothiazolidine-4-carboxylate as a cysteine precursor: efficacy for growth and hepatic glutathione synthesis in chicks and rats. J. Nutr., 1990, 120(2), 158-165.
43. Ionescu, C.; Caira, M. R. Pathways of biotransformation - phase ii reactions. Drug Metab., 2005, 129-170.
44. Habig, W. H.; Pabst, M. J. Glutathione-S-transferases: the first enzymatic step in mercapturic acid formation. J. Biol. Chem., 1974, 249, 7130-7139.
45. La Roche, S. D.; Leisinger T. Sequence analysis and expression of the bacterial dichloromethane dehalogenase structural gene, a member of the glutathione-S-transferase supergene family. J. Bacteriol., 1990, 172, 164-171.
46. Falany, J. L.; Falany, C. N. Regulation of estrogen activity by sulfation in human MCF-7 breast cancer cells. Oncol. Res., 1997, 9, 589-96.
47. Hein, D. W.; Doll, M. A.; Fretland, A. J.; Leff, M. A.; Webb, S. J.; Xio, G. H. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomark. Prev., 2002, 9, 29-42.
48. Payton, M.; Smelt, V.; Upton, A. A method for genotyping murine arylamine N-acetyltransferase type2 (NAT2): A gene expressed in preimplantation embryonic stem cells encoding an enzyme acetylating the folate catabolite p-aminobenzoylglutamate. Biochem. Pharmacol., 1999, 58, 779-785.
49. Josephy, P. D.; Guengerich, F. P.; Miners J. O. Phase I and phase II drug metabolism: terminology that we should phase out? Drug Metab. Rev., 2005, 37(4), 575 - 580.
50. Belanger, A.; Hum, D. W.; Beaulieu, M.; Levesque, E. Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues. J. Steroid Biochem. Mol. Biol., 1998, 65, 301-310.
51. Strassburg, C.; Manns, M. P. Expression of the UDP-glucuronosyl transferase 1A locus in human colon. J. Biol. Chem., 1998, 273, 8719-8726.
52. Tukey, R. H.; Strassburg, C. P. Genetic multiplicity if the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol. Pharmacol., 2001, 59, 405-414.
53. Iwata, H.; Tsuchiya, S.; Ueno, K. Morphine-6-glucuronide induces contraction of the ileal circular muscle more potently than morphine in mice. Eur. J. Pharmacol., 2008, 600(1-3), 130-132.
54. Bray, K.; Quast, U. Some degree of overlap exists between the K1- channels opened by cromakalim and those opened by minoxidil sulphate in rat isolated aorta. Naunyn-Schmeidbergs Arch. Pharmacol. 1991, 344, 351-359.
55. Bonvier, E.; Thirot, S.; Schmidt, F.; Monneret, C. A new paclitaxel prodrug for use in ADEPT strategy. Org. Biomol. Chem., 2003, 1, 3343-3352.
56. Heaney, R. P. The Vitamin D requirement in health and disease. J. Steroid. Biochem. Mol. Biol, 2005, 97, 13-19.
57. During, A.; Nagao, A.; Terao, J. --Carotene 15,15'-dioxygenase activity and cellular retinol-binding protein type ii level are enhanced by dietary unsaturated triacylglycerols in rat intestines. J. Nutr., 1998, 128(10), 1614-1619.
58. Stearns, R. A.; Chakravarty, P. K.; Chen, R. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: role of cytochrome P-4502C and 3A subfamily members. Drug Metab. Dispos., 1995, 23, 207-215.
59. Yun, C. H.; Lee, H. S.; Lee, H.; Jeong, J. K. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes: role of cytochrome P-4503A(4) in formation of the active metabolite Exp3174. Drug Metab. Dispos., 1995, 23, 285-289.
60. Vial, H. J.; Wein, S.; Farenc, C.; Kocken, C. Prodrugs of bisthiazolium salts are orally potent antimalarials. Proc. Natl. Acad. Sci., 2004, 101(43), 15458-15463.
61. Pacholczyk, T.; Blakely, R. D. Trends in the development of new antidepressants. Is there a light at the end of the tunnel? Nature, 1991, 350, 350-354.
62. Bodor, N. Retrometabolic drug design concepts in ophthalmic target-specific drug delivery. Adv. Drug Deliv. Rev., 1995, 16(1), 21-38.
63. Erion M. D.; van Poelje, P. D.; MacKenna, D. A.; Colby, T. Livertargeted drug delivery using direct prodrugs psychopharmacolgy. J. Pharmacol. Exp. Ther., 2005, 312, 554-560.
64. de Waziers I.; Cugnenc, P. H.; Yang, C, S.; Leroux, J. P. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther., 1990, 253, 387-394.
65. Bodor, N.; Shek, E.; Higuchi, T. Delivery of a quaternary pyridinium salt across the blood-brain barrier by its dihydropyridine derivative. Science, 1975, 190, 155 - 156.
66. Cox, P. J.; Farmer, P. B.; Foster, A. B.; Gilby, E. D. The use of deuterated analogs in qualitative and quantitative investigations of the metabolism of cyclophosphamide (NSC-26271). Cancer Treat. Rep., 1976, 6, 483-491.
67. Cox, P. J.; Farmer, P. B.; Jarman, M.; Jones, M. Observations on the differential metabolism and biological activity of the optical isomers of cyclophosphamide. Biochem. Pharmacol., 1976, 25, 993-996.
68. Wilk, S.; Mizoguchi, H.; Orlowski, M. g-Glutamyl dopa: a kidneyspecific dopamine precursor. J. Pharmacol. Exp. Ther., 1978, 206, 227-232.
69. Pawlowski, L.; Nowak, G.; Mazela, H. Ro 11-2465 (cyanimipramine), citalopram and their N-desmethyl metabolites: Effects on the uptake of 5-hydroxytryptamine and noradrenaline in vivo and related pharmacological activities. Psychopharmacolgy, 1985, 86(1-2), 156-163.
70. Hollister, L. E.; Claghorn J. L. New Antidepressants. Annu. Rev. Pharmacol. Toxicol., 1993, 33, 165-177.
71. Chiba, M.; Fujita, S.; Suzuki, T. Pharmacokinetic correlation between in vitro hepatic microsomal enzyme kinetics and in vivo metabolism of imipramine and desipramine in rats. J. Pharm. Sci., 1990, 79, 281-287.
72. Robertson, D.W.; Katzenellenbogen, J. A. Synthesis of the (E) and (Z) isomers of the antiestrogen tamoxifen and its metabolite, hydroxytamoxifen, in tritium-labeled form. J. Org. Chem., 1982, 47, 2387-93.
73. Curran, M.; Noble, S. Valganciclovir. Drugs, 2001, 61(8), 1145-50.
74. Maeda, K.; Nakata, H.; Koh, Y.; Miyakawa, T.; Ogata, H. Spirodiketopiperazine-based CCR5 inhibitor which preserves CCchemokine/ CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J. Virol., 2004, 78(16), 8654-8662.
75. Yoshimura, R.; Yanagihara, N.; Terao, T.; Minami, K. An active metabolite of carbamazepine, carbamazepine-10, 11-epoxide, inhibits ion channel-mediated catecholamine secretion in cultured bovine adrenal medullary cells. Psychopharmacology, 1998, 135(4), 368-373.
76. Rao, G.S.; Ramesh, S.; Ahmad, A.H. Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intramuscular administration of enrofloxacin in goats. Vet. Res. Commun., 2001, 25(3), 197-204.
77. Reznik, I.; Rosen, Y.; Rosen, B. An acute ischaemic event associated with the use of venlafaxine: a case report and proposed pathophysiological mechanisms. J. Psychopharmacol., 1999, 13(2), 193-195.
78. Czejka M.; Schueller J.; Eder I.; Reznicek G. Clinical pharmacocinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. Anticancer. Res., 2000, 20,3871.
79. Matera, M. G. Pharmacologic characteristics of prulifloxacin. Pulm. Pharmacol. Ther., 2006, 19(1), 20-29.
80. Jaglan, P. S.; Kubicek, M. F. Metabolism of ceftiofur. Nature of urinary and plasma metabolites in rats and cattle. J. Agric. Food. Chem., 1989, 37, 1112-1118.
81. Fenton, M.; Morris, S.; De Silva, P. Review: zotepine was as effective as typical and other atypical antipsychotics and more effective than placebo in schizophrenia. Evid. Based Mental Health, 2000, 3, 78.
82. Cone, E. J.; Darwin, W. D.; Buchwald, W. F. Oxymorphone metabolism and urinary excretion in human, rat, guinea pig, rabbit, and dog. Drug. Metab. Dispos., 1983, 11, 446-50.
83. Rosenkranz, V.; Profozic, Z.; Metelko, V.; Mrzljak, C. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment, Diabetologia, 1996, 39(12), 1617-1624.
84. Liu, X.; Li, L.; Sun, J.; Sun, Y.; Zhang, T.; Chen, D.; He, Z. Development and validation of LC coupled with SPE for simultaneous determination of lamivudine, oxymatrine and its active metabolite matrine in dog plasma. Chromatographia, 2006, 63(9-10), 483-486.
85. Gulseth, M. P. Ximelagatran: An orally active direct thrombin inhibitor, Am. J. Health-Syst. Ph., 2005, 62(14), 1451-1467.
86. Nave, R.; Bethke, T. D.; van Marle, S. P.; Zech, K. Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet., 2004, 43, 479-486.
87. Yuan, B.; Wang, X.; Zhang, F.; Jia, J. Simultaneous determination of ramipril and its active metabolite ramiprilat in human plasma by LC-MS-MS. Chromatographia, 2008, 68(7-8), 533-539.
88. Dayer, P.; Desmeules, C. Pharmacology of tramadol. Drugs, 1997, 53(2), 18-24.
89. Baldwin, C. M.; Keam, S. J. Rabeprazole: A Review of its Use in the Management of Gastric Acid-Related Diseases in Adults. Drugs, 2009, 69(10), 1373-1401.